

# 3<sup>rd</sup> Annual Tennessee Oncology Pharmacists Association Meeting

September 29<sup>th</sup>, 2018  
Belmont University, Nashville, TN

Target Audience: Pharmacists

## Registration Fees:

Belmont Full Time Faculty/Student: \$20  
Early Registration (TOPA member, through August 20): \$100  
Early Registration (non-member, through August 20): \$125  
Registration (August 21-September 14): \$150  
NPs, PAs, Nurses- \$30  
Residents- \$0

## Program Agenda

- 8:15am-9:15am - What's New and Novel with Nuclides and Neuroendocrine Neoplasms? (0.1 CEUs)  
UAN: 0863-0000-18-081-L01-P
  - o Jonathan Aston, PharmD, BCOP
  - o Objectives
    - Recognize the role of current anticancer therapies in the management of gastrointestinal neuroendocrine tumors
    - Explain treatment strategies for symptom management in patients with carcinoid syndrome
    - Discuss the evolving use of theranostics within gastrointestinal neuroendocrine tumors
    - Describe the complexities and intricacies involved with lutetium-177 dotatate therapy
  
- 9:15am-9:45am - Role of the Pharmacist in Outpatient Autologous Stem Cell Transplant (0.05 CEUs)  
UAN: 0863-0000-18-082-L01-P
  - o LeAnne Kennedy, PharmD, BCOP, FHOPA
  - o Objectives
    - Discuss the daily roles of the pharmacist with outpatient autologous stem cell transplant
    - Review the potential cost savings associated with outpatient autologous stem cell transplant
  
- 10:00am-11:00am - Updates in Prostate Cancer (0.1 CEUs)  
UAN: 0863-0000-18-083-L01-P
  - o Heather Nelkin, PharmD, BCOP
  - o Objectives
    - Briefly review the pathophysiology of metastatic prostate cancer
    - Discuss pharmacotherapy options for treatment of metastatic prostate cancer
    - Review new literature in the treatment of metastatic prostate cancer
    - Evaluate a patient case related to the management of metastatic prostate cancer
  
- 11:00am-11:30am - The Cost of Cancer and the Role of the Oncology Pharmacist (0.05 CEUs)

UAN: 0863-0000-18-084-L01-P

- Kendall Shultes, PharmD
- Objectives
  - Describe the benefits and barriers of utilizing a dose-rounding policy for chemotherapy/biotherapy
  - Discuss payments options for high-cost drugs and their implication on the role of the oncology pharmacist

- 11:30am-12:00pm - Ongoing Payment Models and Reimbursement Systems for Oncology Infusion Medications (0.05 CEUs)

UAN: 0863-0000-18-085-L01-P

- Alexander Quesenberry, PharmD, BCOP, BCPS
- Objectives
  - Discuss the CMS reimbursement cuts to 340b reimbursement outpatient claims
  - Calculate projected reimbursements from outpatient claims
  - Discuss reimbursement of newly approved medications, biosimilar and pass through status medications
  - Determine medication procurement strategy and sourcing (white, brown, clear, grey bagging)

- 1:00pm-1:30pm - Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation: New Strategies and Novel Pathways (0.05 CEUs)

UAN: 0863-0000-18-086-L01-P

- David Eplin, PharmD, BCOP
- Objectives
  - Describe the prophylactic and pre-emptive treatment strategies for CMV reactivation in HSCT, including current recommendations for standard treatment guidelines
  - Recall different pharmacologic agents with anti-CMV activity, including the recently FDA-approved letermovir, such as: dosing, route, frequency, adverse effects, and other pertinent warnings
  - Review and analyze the published literature regarding letermovir in primary prophylaxis against CMV reactivation in seropositive allogeneic stem cell transplant patients
  - Evaluate letermovir's current role and future areas for research in the treatment and prophylactic modalities for CMV reactivation in this patient population

- 1:30pm-2:30pm - An Update on Treatment of Metastatic Renal Cell Carcinoma (mRCC) (0.1 CEUs)

UAN: 0863-0000-18-087-L01-P

- Renee McAlister, PharmD, BCOP
- Objectives
  - Review the pathophysiology of mRCC
  - Explore new first-line treatment options for mRCC
  - Discuss future directions for treatment of mRCC

- 2:45pm-3:15pm - Creating and Maintaining Ambulatory Student Rotations (0.05 CEUs)

UAN: 0863-0000-18-088-L01-P

- Bridgette Schroader, PharmD, BCOP
- Objectives
  - Present a single center's embedded student ambulatory model
  - Discuss the identification of appropriate student level activities

- Describe the obstacles associated with student rotations in ambulatory settings and specifically in oncology patient clinics
- 3:15pm-3:45pm - Tumor Agnostic Therapies and Clinical Trial Design (0.05 CEUs)  
UAN: 0863-0000-18-089-L01-P
  - Megan Pollack, PharmD, BCOP, BCPS
  - Objectives
    - Identify the FDA-approved tumor agnostic therapies and potential tumor agnostic therapies in the drug development pipeline
    - Recognize the barriers for development of tumor agnostic therapies
    - Discuss clinical trial design as it pertains to tumor agnostic therapies and how these trials differ from typical clinical trial designs in oncology
- 3:45pm-4:15pm - Ruxolitinib: JAK of all trades (0.05 CEUs)  
UAN: 0863-0000-18-090-L01-P
  - Deni Trone, PharmD
  - Objectives
    - Explain the mechanism of action of ruxolitinib
    - Discuss indications for ruxolitinib
    - Evaluate the literature supporting ruxolitinib use in various indications  
Formulate a conclusion for ruxolitinib's place in practice
- 4:15pm-4:45pm - Collaborative Pharmacy Practice Agreement: the road to becoming a provider (0.05 CEUs)  
UAN: 0863-0000-18-091-L01-P
  - Scott Thompson, RPh
  - Objectives
    - Describe a Collaborative Pharmacy Practice Agreement
    - Understand the need and benefits of an agreement
    - Highlight Tennessee legislature that allows for CPPAs
    - Discuss the process of putting an agreement into practice
- 4:45-5:45 - New Drug Updates (0.1 CEUs)  
UAN: 0863-0000-18-092-L01-P
  - Mona Benrashid, PharmD, BCOP
  - Objectives
    - Identify notable drug approvals over the last year
    - Discuss mechanisms of action
    - Summarize pertinent clinical studies
    - Review indications, doses, adverse events, drug interactions and pertinent patient counseling points
    - Highlight clinical impact and potential role in therapy

Thank you to our exhibitors Abbvie, Amgen, BMS, Eisai, Jazz, Lilly, Merck.



Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. These knowledge-based activities provide up to 8.00 contact hours (.80 CEUs) of continuing education credit. Continuing education statements of credit will be available to attendees who attend the live seminars and complete the online evaluation.